GC Biopharma launches 온라인 바카라 사이트 center in Laredo, U.S., moving early to outpace ALYGLO's expansion

[by Yu, Suin] GC Biopharma announced on September 16 (local time) that its U.S. subsidiary, ABO 온라인 바카라 사이트 (formerly ABO Holdings), has inaugurated the Laredo 온라인 바카라 사이트 Center in Texas.

ABO 온라인 바카라 사이트 will begin recruiting 온라인 바카라 사이트 donors immediately following the opening of the Laredo 온라인 바카라 사이트 Center. The collected 온라인 바카라 사이트, which has a shelf-life of 24 months, will be stored and prepared for sale immediately upon completion of U.S. Food and Drug Administration (FDA) approval. As the FDA approval process for 온라인 바카라 사이트 centers generally requires approximately nine months, ABO 온라인 바카라 사이트 anticipates securing approval in the first half of 2026.

The Laredo 온라인 바카라 사이트 Center, initially scheduled for completion in 2026, was expedited to align with the growth of ALYGLO and the rising demand for 온라인 바카라 사이트-derived products in the domestic market. In addition, the Eagle Pass 온라인 바카라 사이트 Center in Texas is expected to open in 2026.

"This year will mark a turning point for the domestic and global 온라인 바카라 사이트 derivatives business to take a leap forward. We are enhancing the competitiveness of this sector by building on a stable supply chain," said Huh Eun-chul, CEO of GC Biopharma.

On the other hand, GC Biopharma's ALYGLO is manufactured using 온라인 바카라 사이트 sourced 100% from the United States. Under Executive Order 14257, issued by the Trump administration, reciprocal tariffs on imports are imposed on non-U.S. components only if the proportion of U.S.-derived ingredients in the finished product exceeds 20%. The 온라인 바카라 사이트 content of ALYGLO, excluding additives, is approximately 50%.